MEDIUM confidence: 100% data completeness, but the composite (55) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2.3B— | $2.2B-2.3% | $2.4B+5.2% | $2.3B-3.9% | $2.4B+5.1% |
| EPS (dil.) | $1.49— | $0.10-93.3% | $2.53+2430.0% | $1.91-24.5% | $1.80-5.8% |
| Free Cash Flow | $2.0B— | $2.1B+6.3% | $3.0B+39.4% | $2.8B-7.3% | $2.5B-10.1% |
| Gross Margin | 100.0% | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp |
| Operating Margin | 62.5% | 13.7%-48.8pp | 63.4%+49.6pp | 57.1%-6.3pp | 65.6%+8.5pp |
| Net Margin | 27.1% | 1.9%-25.2pp | 48.2%+46.3pp | 37.9%-10.2pp | 32.4%-5.5pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Buy-rated share 82% → 78% over ~3 months (-4pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $1.27 | $1.32 | +3.9% |
| May 2026 | $1.21 | $1.30 | +7.4% |
| Feb 2026 | $1.29 | $1.46 | +13.2% |
| Nov 2025 | $0.99 | $1.17 | +17.7% |
| Aug 2025 | $1.03 | $1.14 | +10.7% |
| May 2025 | $0.95 | $1.06 | +11.2% |
| Feb 2025 | $0.99 | $1.15 | +16.2% |
| Nov 2024 | $0.93 | $1.04 | +12.1% |
Net insider -$22.5M over 180 days (0 open-market buys, 20 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth below the analyst consensus of 9.0%/yr (revenue basis).
Base free cash flow $2.7B (avg FY2023–FY2025; latest year $2.5B) · equity value $26.1B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 55 indicates a neutral outlook for RPRX, driven by a mix of factors. The stock scores high on profitability, with a strong operating margin of 62.3% and ROE of 12.3%, but is held back by relatively low growth and value scores, with a P/E of 24.4 and revenue growth of 5.1%. Momentum is a positive factor, with a 12-month return of 64.0% and a bullish moving average trend, while risk metrics are moderate, with a low beta of 0.4.